bacteria biofilm indwelling catheter

First New Urinary Catheter for 80 Years to Be Revealed

The inventors of a new catheter claim it could solve one of “the biggest problems” in community nursing and reduce discomfort, embarrassment and complications for millions of patients.  They are nearing the final stages of developing their new Flume Catheter, which they hope will solve many of the common problems associated with current models, and are calling on nurses to help them with their ongoing research.  Their design, which was also developed with input from community nurses, is less likely to block and also less of an infection risk than older models, according to the clinicians and engineers behind it. Read more.

Source: Nursing Times, November 15, 2017

Botox injection overactive bladder

Sacral Neuromodulation, Botulinum Show Equal Efficacy

In patients with refractory urgency urinary incontinence (UUI), sacral neuromodulation (InterStim) and onabotulinumtoxinA (Botox) produce similar reductions in mean daily UUI episodes, according to 24-month follow-up data on patients treated in a randomized trial.  Investigators in the ROSETTA (Refractory Overactive Bladder: Sacral NEuromodulation versus BoTulinum Toxin Assessment) trial in 2016 reported that botulinum toxin at 6 months of treatment resulted in a “small daily improvement in UUI episodes” that was statistically significant (JAMA 2016; 316:1366–74).  Now, in long-term follow-up data on ROSETTA, NIH investigators reported at the International Continence Society annual meeting in Florence, Italy that the two treatments provide similar reductions in mean daily UUI episodes at 24 months. However, botulinum toxin treatment was more likely to provide complete resolution of episodes 6 months after treatment, and it was associated with higher patient satisfaction and treatment endorsement ratings over the 24 months, reported first author Christopher J. Chermansky, MD, assistant professor of urology at the University of Pittsburgh School of Medicine. Read more.

Source: Urology Times, November 14, 2017

 

e. coli bacteria

Innovus Pharma Announces Agreement with ACON Laboratories, Inc.

Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced that it has entered into an agreement with ACON Laboratories, Inc. (“ACON Labs”). ACON Labs is a San Diego-based diagnostic product manufacturer who will supply Innovus Pharma with its U.S. Food and Drug Administration’s (“FDA”) cleared Urinary Tract Infection (“UTI”) test strips. Innovus Pharma will offer the UTI test strips, which provide results in 2-minutes, to its customers who buy its UriVarx™ product. UriVarx™ is clinically tested in patients with overactive bladder (“OAB”) and urinary incontinence (“UI”). Innovus Pharma is expected to launch the UTI strips under its UriVarx™ brand in Q1 2018. Read more.

Source: Market Insider, November 9, 2017

business buildings

Allergan Partners with Urine Incontinence Treatment Company

Allergan is conducting clinical trials for a Botox-based bladder treatment, using a sustained release gel developed by Israel-based UroGen. Allergan Pharmaceuticals International Ltd., a wholly owned subsidiary of Allergan PLC, has started a phase 2 clinical trial for the treatment of overactive bladder. The trial will combine Botox with a sustained release gel called RTGel, developed by Nasdaq-listed UroGen Pharma Ltd., a clinical stage company developing non-surgical urology treatments. RTGel is a temperature-sensitive substance that changes from a liquid to a gel when it reaches body temperature. These properties enable a slower release of drugs in the body when mixed with the gel. Botox is already in use for treating overactive bladder, since it relaxes the nerves that over-stimulate the bladder muscles and lead to frequent urination. Read more.
Source: CTECH, November 8, 2017
product approval

Axonics® Receives IDE Clearance from US FDA to Conduct Pivotal Study

Axonics Modulation Technologies, Inc., developer of the first rechargeable sacral neuromodulation (r-SNM™) system for the treatment of overactive bladder (OAB) and bowel dysfunction, today announced the U.S. Food & Drug Administration (FDA) has granted an Investigational Device Exemption (IDE) in accordance with 21 CFR 812 regulations allowing Axonics to conduct a pivotal study designed to gain FDA approval in the United States.  “During 2017, as part of the IDE process, the FDA conducted a significant review of our product. A major focus of the technical review was the long-term safety of our implant. The fact that we were able to support our anticipated 15-year full system life-in-the-body claim based on our robust design and development processes, risk analysis and extensive validation testing is testament to the high-quality work of our team,” said Raymond W. Cohen, Chief Executive Officer of Axonics. “Given the demand in the U.S. market for SNM therapy, gaining FDA approval is our main focus. To that end, we fully intend to execute this well-designed pivotal study with velocity and in the best interests of patients.” Read more.

Source: Pharmaweb, November 7, 2017

Apple iPhone

Crohn’s and Colitis Canada Wants Businesses to Open Their Washrooms to Those In Need

Crohn’s and Colitis Canada is taking aim at a serious hurdle many Canadians with Crohn’s disease or ulcerative colitis face – accessing washrooms on the go. November is Crohn’s and Colitis Awareness Month, and the national charity is advocating that public washroom access is a right, not a privilege, and for the Canadians living with these chronic diseases, it’s a critical need.  Crohn’s and colitis are debilitating, yet often invisible, autoimmune diseases. They cause the body to attack healthy tissue, leading to the inflammation of all or part of the digestive tract. Symptoms include diarrhea, internal bleeding, and abdominal pain, and result in the frequent and urgent need to use the washroom, in some cases over 20 times a day.  Read more.

Source: CNW, November 1, 2017

doctor and patient

November Marks National Bladder Health Month

November is National Bladder Health Month and, for a second year, the Urology Care Foundation, American Urological Association (AUA) and the Bladder Health Alliance – a coalition of groups representing physicians, patients and veterans – have teamed up to support Bladder Health Month. Designed to raise awareness about bladder conditions, encourage individuals to talk with their healthcare providers about the symptoms they are experiencing and to generate support for those affected by bladder health issues, this month-long awareness campaign was developed to increase an individual’s focus on “Getting the Facts, Getting Diagnosed and Taking Control” of their Bladder Health. Read more.

Source: Markets Insider, November 1, 2017

women friends

Women Have Many Treatment Options for Urinary Incontinence

Roughly half of adult women may experience urinary incontinence, but few of them get diagnosed and treated despite a wide range of options to address the problem, doctors say.  Women are particularly prone to stress urinary incontinence, when the pelvic floor muscles are too weak to support the bladder. As a result, urine leaks during coughing, sneezing or exercise. Childbirth is a common reason for weak pelvic muscles, and obesity worsens the problem. Urge incontinence, in contrast, doesn’t have a clear cause, although it can sometimes happen due to neurological problems, the authors note. Some women may get both types of incontinence at once or develop bladder problems due to a urinary tract infection. Read more.

Source: Reuters, October 24, 2017

doctor male discussion

Trouble Urinating? New Technique Can Help Men with Enlarged Prostate (BPH)

Men: As you age, there’s a good chance you may get up several times a night to empty your bladder. The problem is that your bladder doesn’t empty completely.  No matter how hard to you try, you can only deliver a trickle before returning to bed. In a few hours, you are up again. The process repeats itself all night.  For many men, this frustrating scenario is the result of an enlarged prostate that is squeezing the urethra, which prevents the bladder from emptying completely. When the problem is caused by a noncancerous condition, it’s called benign prostatic hypertrophy (BPH).  Until recently, the only way to free the urethra and restore urine flow was to have a physician cut or vaporize the prostate. But this surgery can leave men with a degree of incontinence or impotence.  A new alternative that uses steam holds promise in treating BPH. Researchers developed an entirely new approach to treating BPH by using steam to kill prostate cells and shrink the prostate. The outpatient procedure is performed in about five minutes using a local anesthetic. Most men see improved urine flow in three to six weeks and dramatic improvement in three months.  Read more.

Source: Cleveland Clinic, October 20, 2017

improve incontinence

New Report Indicates No Evidence AHT Pelvic Exercise Works

Abdominal hypopressive technique (AHT), an exercise method widely touted for 20 years as a way of controlling bladder leakage and pelvic organ prolapse, doesn’t work, according to a new report.  AHT is a breathing exercise developed in the 1980s by Belgian physiotherapist Marcel Caufriez. Highly popular, it is taught by more than 1500 practitioners in 14 countries, including in Australia.  But a report published last week in the British Journal of Sports Medicine finds no scientific evidence to support the claimed benefits of AHT.  Authors Kari Bo, of the Norwegian School of Sport Sciences, in Oslo, and Saul Martín-Rodríguez, of the College of Physical Education, in Las Palmas, Spain, acknowledge the “worldwide huge interest” in AHT but say it “lacks scientific evidence to support its benefits. At this stage, AHT is based on a theory with 20 years of clinical practice.” Read more.

Source: Cosmos Magazine, October 18, 2017